Mortality-related risk factors of inpatients with diabetes and COVID-19: A multicenter retrospective study in Belgium
- PMID: 37574109
- DOI: 10.1016/j.ando.2023.08.002
Mortality-related risk factors of inpatients with diabetes and COVID-19: A multicenter retrospective study in Belgium
Abstract
Background and aims: We describe mortality-related risk factors of inpatients with diabetes and coronavirus disease 2019 (COVID-19) in Belgium.
Methods: We conducted a multicenter retrospective study from March to May, 2020, in 8 Belgian centers. Data on admission of patients with diabetes and COVID-19 were collected. Survivors were compared to non-survivors to identify prognostic risk factors for in-hospital death using multivariate analysis in both the total population and in the subgroup of patients admitted in the intensive care unit (ICU).
Results: The study included 375 patients. The mortality rate was 26.4% (99/375) in the total population and 40% (27/67) in the ICU. Multivariate analysis identified older age (HR 1.05 [CI 1.03-1.07], P<0.0001) and male gender (HR 2.01 [1.31-3.07], P=0.0013) as main independent risk factors for in-hospital death in the total population. Metformin (HR 0.51 [0.34-0.78], P=0.0018) and renin-angiotensin-aldosterone system blockers (HR 0.56 [0.36-0.86], P=0.0088) use before admission were independent protective factors. In the ICU, chronic kidney disease (CKD) was identified as an independent risk factor for death (HR 4.96 [2.14-11.5], P<0.001).
Conclusion: In-hospital mortality due to the first wave of COVID-19 pandemic in Belgium was high in patients with diabetes. We found that advanced age and male gender were independent risk factors for in-hospital death. We also showed that metformin use before admission was associated with a significant reduction of COVID-19-related in-hospital mortality. Finally, we showed that CKD is a COVID-19-related mortality risk factor in patients with diabetes admitted in the ICU.
Keywords: Chronic kidney disease; Metformin; Pneumonia; Prognosis; SARS-CoV-2.
Copyright © 2023 Elsevier Masson SAS. All rights reserved.
Comment in
-
Optimizing antidiabetic therapy: Enhancing COVID-19 outcomes for patients with type-2 diabetes.Ann Endocrinol (Paris). 2023 Dec;84(6):792. doi: 10.1016/j.ando.2023.09.004. Epub 2023 Oct 17. Ann Endocrinol (Paris). 2023. PMID: 37903668 No abstract available.
-
Authors' reply to correspondence to "Mortality-related risk factors of inpatients with diabetes and COVID-19: A multicenter retrospective study in Belgium. Ann Endocrinol (Paris). 2023 Aug 31:S0003-4266(23)00685-6. doi: 10.1016/j.ando.2023.08.002".Ann Endocrinol (Paris). 2023 Dec;84(6):790-791. doi: 10.1016/j.ando.2023.10.001. Epub 2023 Oct 17. Ann Endocrinol (Paris). 2023. PMID: 37951796 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous